Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Healthy Community Project

- PMLiVE

Sanofi gets US okay for $270,000 blood disorder drug Cablivi

First in a new class of single-domain antibody fragments drugs

- PMLiVE

Trulicity’s ascent lifts Lilly

Diabetes treatment leads new product growth

- PMLiVE

Sanofi’s Darzalex rival scores in myeloma trial

Antibody first to show benefit in combination setting

- PMLiVE

Novo Nordisk preps for speedy oral GLP-1 drug filing

Needs to compete with rival's fast-growing Trulicity

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

- PMLiVE

GSK and Sanofi join Finland’s 500,000 genomics study

AstraZeneca, MSD and Pfizer already participating

- PMLiVE

Rising economic risk casts shadow on Davos meeting

Slowing growth in key economies causing concern

China’s clinical trial shake-up

As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location

Sanofi reception

FDA adcomm split on Sanofi’s type 1 diabetes drug

Concerns rose after Zynquista-treated patients showed an eight-fold increase in DKA

- PMLiVE

China approves Ironwood Pharma’s IBS treatment

Coincides with AZ's Mark Mallon taking over as CEO

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

Sanofi reception

Sanofi and Regeneron re-jig immuno-oncology deal

Partners refocus around two promising bispecific candidates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links